This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PN2034
Description: PN2034 is part of the PN2000 series of orally active antidiabetic agents that normalize both glucose and lipid levels in preclinical rodent models.
PN2034 is a non-TZD PPAR modulator with a mechanism physiologically distinguishable from activation of PPAR-alpha, PPAR-gamma, or both. However, this compound also inhibits PPAR-alpha activation by the PPAR-alpha agonist, WY-14643.
In rodent studies, PN2034 increased PPAR-alpha activity and selectively increased PPAR-alpha in some cell lines.
Deal Structure: PN2034 was originally developed by Wellstat Therapeutics.
In October 2009, sanofi-aventis and Wellstat Therapeutics announced a global licensing agreement on PN2034. Under this agreement, sanofi-aventis will receive an exclusive worldwide license to develop, manufacture and commercialize PN2034 and related compounds.
Under the terms of the agreement, Wellstat Therapeutics will receive an upfront cash payment for the development, manufacturing and commercialization rights, and is eligible for development and regulatory milestone payments. The total of all those payments could reach $350 million. Wellstat Therapeutics will also receive royalties on the worldwide product sales and performance based sales milestones.
Partners: Wellstat Therapeutics Corporation
Additional information available to subscribers only: